POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 69 / 2021

Date of preparation: 2021-12-20

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Ukraine

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

The Management Board of Mabion S.A. ("Company") hereby informs that on 20 December 2021, the Company became aware that the Minister of Health in Ukraine has issued an authorisation ("Authorisation") for the Company to conduct a clinical trial of MabionCD20 in patients with rheumatoid arthritis ("RA") in Ukraine. The Company also holds approval of the competent bioethics committee in this regard.

The authorisation by the Minister of Health enables the extension of the bridging clinical trial to include Ukraine. The Company has already obtained authorisations to conduct the trial in Poland, Georgia, and Belgium. The Company does not exclude that the trial may also be extended to other countries.

Detailed information on the parameters of the bridging clinical trial was provided in Current Report no. 53/2021 of 11 October 2021.